Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc.verified

INTI

Price:

$0.05

Market Cap:

$8.63M

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.

Industry

Biotechnology

IPO Date

2013-09-13

Stock Exchange

OTC

Ticker

INTI

The PE Ratio as of December 2025 (TTM) for Inhibitor Therapeutics, Inc. (INTI) is -2.50

According to Inhibitor Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.50. This represents a change of -8.82% compared to the average of -2.74 of the last 4 quarters.

Inhibitor Therapeutics, Inc. (INTI) Historical PE Ratio (quarterly & annually)

How has INTI PE Ratio performed in the past?

The mean historical PE Ratio of Inhibitor Therapeutics, Inc. over the last ten years is -25.95. The current -2.50 PE Ratio has changed 863.22% with respect to the historical average. Over the past ten years (40 quarters), INTI's PE Ratio was at its highest in in the December 2022 quarter at 0.73. The PE Ratio was at its lowest in in the December 2021 quarter at -420.92.

Quarterly (TTM)
Annual

Average

-25.95

Median

-7.38

Minimum

-188.75

Maximum

2.99

Inhibitor Therapeutics, Inc. (INTI) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Inhibitor Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 1.43%

Maximum Annual PE Ratio = 2.99

Minimum Annual Increase = -253.63%

Minimum Annual PE Ratio = -188.75

Quarterly (TTM)
Annual
YearPE RatioChange
2024-3.10-32.60%
2023-4.60-253.63%
20222.99-101.59%
2021-188.751.43%
2020-12.3273.22%
2019-7.1145.79%
2018-4.88-72.97%
2017-18.0412.14%
2016-16.09110.14%
2015-7.66153.90%

Inhibitor Therapeutics, Inc. (INTI) Average PE Ratio

How has INTI PE Ratio performed in the past?

The current PE Ratio of Inhibitor Therapeutics, Inc. (INTI) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-1.57

5-year avg

-41.16

10-year avg

-25.95

Inhibitor Therapeutics, Inc. (INTI) PE Ratio vs. Peers

How is INTI’s PE Ratio compared to its peers?

Inhibitor Therapeutics, Inc.’s PE Ratio is less than LianBio (4.68), less than Oxford BioDynamics Plc (-0.17), greater than Devonian Health Group Inc. (-3.39), less than Chimeric Therapeutics Limited (-0.76), less than Quantum Genomics S.A. (-0.79), less than Curative Biotechnology, Inc. (-2.42), greater than Nymox Pharmaceutical Corporation (-3.59), greater than BetterLife Pharma Inc. (-4.01), greater than PharmaTher Holdings Ltd. (-4.36), greater than Nass Valley Gateway Ltd. (-3.70),

Build a custom stock screener for Inhibitor Therapeutics, Inc. (INTI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inhibitor Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Inhibitor Therapeutics, Inc. (INTI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Inhibitor Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Inhibitor Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Inhibitor Therapeutics, Inc. (INTI)?

What is the highest PE Ratio for Inhibitor Therapeutics, Inc. (INTI)?

What is the 3-year average PE Ratio for Inhibitor Therapeutics, Inc. (INTI)?

What is the 5-year average PE Ratio for Inhibitor Therapeutics, Inc. (INTI)?

How does the current PE Ratio for Inhibitor Therapeutics, Inc. (INTI) compare to its historical average?